Entity Central Index Key
Cover [Abstract]
Document Type
Document Type
Amendment Flag
Amendment Flag
Document Period End Date
Document Period End Date
Document Fiscal Year Focus
Document Fiscal Year Focus
Document Fiscal Period Focus
Document Fiscal Period Focus
Trading Symbol
Trading Symbol
Entity Registrant Name
Entity Registrant Name
Entity Central Index Key
Current Fiscal Year End Date
Current Fiscal Year End Date
Entity Current Reporting Status
Entity Current Reporting Status
Entity Filer Category
Entity Filer Category
Entity Small Business
Entity Small Business
Entity Emerging Growth Company
Entity Emerging Growth Company
ICFR Auditor Attestation Flag
Icfr Auditor Attestation Flag
Entity Shell Company
Entity Shell Company
Entity Well-known Seasoned Issuer
Entity Well Known Seasoned Issuer
Entity Voluntary Filers
Entity Voluntary Filers
Entity Interactive Data Current
Entity Interactive Data Current
Title of 12(b) Security
Security12b Title
Security Exchange Name
Security Exchange Name
Entity File Number
Entity File Number
Entity Incorporation, State or Country Code
Entity Incorporation State Country Code
Entity Tax Identification Number
Entity Tax Identification Number
Entity Address, Address Line One
Entity Address Address Line1
Entity Address, Address Line Two
Entity Address Address Line2
Entity Address, City or Town
Entity Address City Or Town
Entity Address, State or Province
Entity Address State Or Province
Entity Address, Postal Zip Code
Entity Address Postal Zip Code
City Area Code
City Area Code
Local Phone Number
Local Phone Number
Entity Common Stock, Shares Outstanding
Entity Common Stock Shares Outstanding
Entity Public Float
Entity Public Float
Document Transition Report
Document Transition Report
Document Annual Report
Document Annual Report
Documents incorporated by reference
Documents Incorporated By Reference [Text Block]
Auditor Firm ID
Auditor Firm Id
Auditor Name
Auditor Name
Auditor Location
Auditor Location
The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer. as well as trade accounts receivable, notes and loans receivable.
Statement Of Financial Position [Abstract]
Assets
Assets [Abstract]
Current assets:
Assets Current [Abstract]
Cash and cash equivalents
Cash And Cash Equivalents At Carrying Value
Accounts receivable
Accounts Receivable Net Current
Prepaid expenses and other current assets
Prepaid Expenses And Other Receivables
Total current assets
Assets Current
Property and equipment, net
Property Plant And Equipment Net
Operating lease right-of-use asset, net
Operating Lease Right Of Use Asset
Equity-method investment
Equity Method Investments
Non-current restricted cash
Restricted Cash Noncurrent
Total assets
Assets
Liabilities and stockholders’ equity
Liabilities And Stockholders Equity [Abstract]
Current liabilities:
Liabilities Current [Abstract]
Accounts payable
Accounts Payable Current
Accrued liabilities
Accrued Liabilities Current
Current portion of long-term debt
Long Term Debt Current
Deferred revenue
Deferred Revenue Current
Total current liabilities
Liabilities Current
Deferred revenue, net of current portion
Deferred Revenue Noncurrent
Long-term debt, net of current portion
Long Term Debt Noncurrent
Operating lease liability, net of current portion
Operating Lease Liability Noncurrent
Total liabilities
Liabilities
Stockholders’ equity:
Stockholders Equity [Abstract]
Common stock: $0.001 par value; 60,000 shares authorized; 26,372 shares issued and outstanding at December 31, 2021 and 26,192 shares issued and outstanding at December 31, 2020
Common Stock Value
Additional paid-in capital
Additional Paid In Capital
Accumulated deficit
Retained Earnings Accumulated Deficit
Total stockholders’ equity
Stockholders Equity
Total liabilities and stockholders’ equity
Liabilities And Stockholders Equity
Common stock, par value
Common Stock Par Or Stated Value Per Share
Common stock, shares authorized
Common Stock Shares Authorized
Common stock, shares issued
Common Stock Shares Issued
Common stock, shares outstanding
Common Stock Shares Outstanding
Statement Of Income And Comprehensive Income [Abstract]
Revenue
Revenue From Contract With Customer Excluding Assessed Tax
Operating expenses:
Operating Expenses [Abstract]
Research and development, net
Research And Development Expense
General and administrative
General And Administrative Expense
Total operating expenses
Operating Expenses
Loss from operations
Operating Income Loss
Gain (loss) from equity-method investment
Income Loss From Equity Method Investments
Foreign currency transaction gain
Foreign Currency Transaction Gain Loss Before Tax
Finance expense, net
Other Nonoperating Income Expense
Net loss
Net Income Loss
Net loss per share, basic and diluted
Earnings Per Share Basic And Diluted
Weighted-average shares outstanding, basic and diluted
Weighted Average Number Of Share Outstanding Basic And Diluted
Comprehensive loss:
Comprehensive Income Net Of Tax [Abstract]
Net loss
Comprehensive loss
Comprehensive Income Net Of Tax
Stock issued during period shares redomiciliation share exchange.
Stock issued during period value, redomiciliation share exchange.
Stock issued during period shares option exercised.
Stock issued during period value option exercised.
Stock issued during period shares under equity plan.
Stock issued during period value under equity plan.
Statement Of Stockholders Equity [Abstract]
Statement [Table]
Statement [Table]
Equity Components
Statement Equity Components [Axis]
Equity Component
Equity Component [Domain]
Common Stock [Member]
Common Stock [Member]
Additional Paid-In Capital [Member]
Additional Paid In Capital [Member]
Accumulated Deficit [Member]
Retained Earnings [Member]
Cumulative Effect, Period of Adoption
Cumulative Effect Period Of Adoption [Axis]
Cumulative Effect, Period of Adoption
Cumulative Effect Period Of Adoption [Domain]
Cumulative Effect, Period of Adoption, Adjustment [Member]
Cumulative Effect Period Of Adoption Adjustment [Member]
Counterparty Name
Counterparty Name [Axis]
Counterparty Name
Repurchase Agreement Counterparty Name [Domain]
Ultragenyx.
Ultragenyx [Member]
Ultragenyx [Member]
Statement [Line Items]
Statement [Line Items]
Balance
Balance (in shares)
Shares Outstanding
Share-based compensation
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
Issuance of common stock related to acquired in-process research and development
Stock Issued During Period Value Acquisitions
Issuance of common stock related to acquired in-process research and development (in shares)
Stock Issued During Period Shares Acquisitions
Issuance of common stock to Ultragenyx on option exercise
Stock Issued During Period Value Option Exercised
Issuance of common stock to Ultragenyx and option, net of issuance costs (in shares)
Stock Issued During Period Shares Option Exercised
Redomiciliation share exchange
Stock Issued During Period Value Redomiciliation Share Exchange
Redomiciliation share exchange (in shares)
Stock Issued During Period Shares Redomiciliation Share Exchange
Issuance of common stock, net of issuance costs
Stock Issued During Period Value New Issues
Issuance of common stock, net of issuance costs (in shares)
Stock Issued During Period Shares New Issues
Issuance of common stock upon exercise of stock options
Stock Issued During Period Value Stock Options Exercised
Issuance of common shares upon exercise of share options (in shares)
Stock Issued During Period Shares Stock Options Exercised
Issuance of common stock under equity plans
Stock Issued During Period Value Under Equity Plan
Issuance of common stock under equity plans (in shares)
Stock Issued During Period Shares Under Equity Plan
Balance
Accounting Standards Update [Extensible Enumeration]
Accounting Standards Update Extensible List
Balance (in shares)
(Gain) loss from equity-method investment.
Proceeds from exercise of stock option and issuance of common stock and option, net of issuance costs.
Acquisition of research and development in process through issuance of common stock.
Statement Of Cash Flows [Abstract]
OPERATING ACTIVITIES:
Net Cash Provided By Used In Operating Activities [Abstract]
Adjustments to reconcile net loss to net cash used in operating activities:
Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract]
Depreciation and amortization
Depreciation And Amortization
Share-based compensation expense
Share Based Compensation
Acquired in-process research and development expense
Research And Development In Process
(Gain) loss from equity-method investment
Gain Loss From Equity Method Investment
Foreign currency transaction gain
Foreign Currency Transaction Gain Loss Realized
Other non-cash expenses
Other Noncash Income Expense
Changes in operating assets and liabilities:
Increase Decrease In Operating Capital [Abstract]
Accounts receivable
Increase Decrease In Accounts Receivable
Prepaid expenses and other assets
Increase Decrease In Prepaid Deferred Expense And Other Assets
Accounts payable
Increase Decrease In Accounts Payable
Accrued liabilities
Increase Decrease In Accrued Liabilities
Deferred revenue
Increase Decrease In Contract With Customer Liability
Net cash used in operating activities
Net Cash Provided By Used In Operating Activities
INVESTING ACTIVITIES:
Net Cash Provided By Used In Investing Activities [Abstract]
Acquisition of property and equipment
Payments To Acquire Property Plant And Equipment
Net cash used in investing activities
Net Cash Provided By Used In Investing Activities
FINANCING ACTIVITIES:
Net Cash Provided By Used In Financing Activities [Abstract]
Proceeds from long-term debt, net of lender fees
Proceeds From Issuance Of Long Term Debt
Proceeds from exercise of stock options
Proceeds From Stock Options Exercised
Proceeds from issuance of common stock under equity plans
Proceeds From Stock Plans
Proceeds from exercise of stock option by Ultragenyx and issuance of common stock and option, net of issuance costs, to Ultragenyx
Proceeds From Exercise Of Stock Option And Issuance Of Common Stock And Option Net Of Issuance Costs
Proceeds from issuance of common stock, net of issuance costs
Proceeds From Issuance Of Common Stock
Net cash provided by financing activities
Net Cash Provided By Used In Financing Activities
NET (DECREASE) INCREASE IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
Cash, cash equivalents and restricted cash at beginning of year
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
Cash, cash equivalents and restricted cash at end of year
Supplemental disclosure of cash flow information:
Supplemental Cash Flow Information [Abstract]
Cash paid for interest
Interest Paid Net
Non-cash investing activities
Cash Flow Noncash Investing And Financing Activities Disclosure [Abstract]
Right-of-use asset obtained in exchange for lease liabilities
Right Of Use Asset Obtained In Exchange For Operating Lease Liability
Acquisition of in-process research and development through issuance of common stock
Acquisition Of Research And Development In Process Through Issuance Of Common Stock
Purchase of property and equipment in accounts payable
Capital Expenditures Incurred But Not Yet Paid
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Organization
Business Description And Accounting Policies [Text Block]
Accounting Policies [Abstract]
Summary of Significant Accounting Policies
Significant Accounting Policies [Text Block]
Revenue From Contract With Customer [Abstract]
Revenue
Revenue From Contract With Customer [Text Block]
Fair Value Disclosures [Abstract]
Fair Value Measurements
Fair Value Disclosures [Text Block]
Balance Sheet Related Disclosures [Abstract]
Balance Sheet Details
Supplemental Balance Sheet Disclosures [Text Block]
Property Plant And Equipment [Abstract]
Property and Equipment, Net
Property Plant And Equipment Disclosure [Text Block]
Debt Disclosure [Abstract]
Debt
Debt Disclosure [Text Block]
Stockholders Equity Note [Abstract]
Stockholders' Equity
Stockholders Equity Note Disclosure [Text Block]
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Share-Based Compensation
Disclosure Of Compensation Related Costs Share Based Payments [Text Block]
Income Tax Disclosure [Abstract]
Income Taxes
Income Tax Disclosure [Text Block]
Commitments And Contingencies Disclosure [Abstract]
Commitments and Contingencies
Commitments And Contingencies Disclosure [Text Block]
Related Party Transactions [Abstract]
Related Party Transactions
Related Party Transactions Disclosure [Text Block]
Subsequent Events [Abstract]
Subsequent Events
Subsequent Events [Text Block]
Quarterly Financial Data [Abstract]
Selected Quarterly Financial Data (Unaudited)
Quarterly Financial Information [Text Block]
Basis of Presentation and Principles of Consolidation
Consolidation Policy [Text Block]
Segment Information
Segment Reporting Policy Policy [Text Block]
Cash and Cash Equivalents
Cash And Cash Equivalents Policy [Text Block]
Restricted Cash
Cash And Cash Equivalents Restricted Cash And Cash Equivalents Policy
Fair Value Measurements
Fair Value Measurement Policy Policy [Text Block]
Accounts Receivable
Receivables Policy [Text Block]
Concentration of Credit Risk and Significant Customers
Concentration Risk Credit Risk
Joint ventures, equity method investments and variable interest entities.
Joint Ventures, Equity Method Investments and Variable Interest Entities
Joint Ventures Equity Method Investments And Variable Interest Entities Policy [Text Block]
Property and Equipment, net
Property Plant And Equipment Policy [Text Block]
Comprehensive Income/Loss
Comprehensive Income Policy Policy [Text Block]
Revenue Recognition
Revenue Recognition Policy [Text Block]
Leases
Lessee Leases Policy [Text Block]
Research and Development Costs, net
Research And Development Expense Policy
Share-Based Compensation
Share Based Compensation Option And Incentive Plans Policy
Pre-launch inventory policy.
Pre-Launch Inventory
Pre Launch Inventory Policy Policy [Text Block]
Statement of Cash Flows
Inventory Cash Flow Policy
Income Tax Expense
Income Tax Policy [Text Block]
Net Loss per Share
Earnings Per Share Policy [Text Block]
Schedule of Cash and Cash Equivalents and Restricted Cash
Schedule Of Cash And Cash Equivalents Table [Text Block]
Summary of Changes in Balances of Contract Assets and Contract Liability
Contract With Customer Asset And Liability Table [Text Block]
Schedule of Revenue
Disaggregation Of Revenue Table [Text Block]
Schedule of Accrued Liabilities
Schedule Of Accrued Liabilities Table [Text Block]
Summary of Components of Property and Equipment
Property Plant And Equipment [Text Block]
Schedule of Maturities of Long-term Debt
Schedule Of Maturities Of Long Term Debt Table [Text Block]
Schedule of Weighted Average Assumptions Used in Black -Scholes Valuation Model
Schedule Of Share Based Payment Award Stock Options Valuation Assumptions Table [Text Block]
Summary of Share Option Activity
Schedule Of Share Based Compensation Stock Options Activity Table [Text Block]
Schedule of Share-based Compensation Expenses
Schedule Of Compensation Cost For Share Based Payment Arrangements Allocation Of Share Based Compensation Costs By Plan Table [Text Block]
Summary of Reconciliation of Loss Before Income Taxes for Domestic and Foreign Locations
Schedule Of Income Before Income Tax Domestic And Foreign Table [Text Block]
Summary of Reconciliation of Unrecognized Tax Benefits
Schedule Of Unrecognized Tax Benefits Roll Forward Table [Text Block]
Significant Components of Deferred Income Taxes
Schedule Of Deferred Tax Assets And Liabilities Table [Text Block]
Reconciliation of Federal Statutory Income Tax Rate to Company's Effective Income Tax Rate
Schedule Of Effective Income Tax Rate Reconciliation Table [Text Block]
Payments of Operating Lease Liability
Lessee Operating Lease Liability Maturity Table [Text Block]
Summary of Quarterly Results
Schedule Of Quarterly Financial Information Table [Text Block]
Organization and significant accounting policies line items.
Organization and significant accounting policies.
Organization And Significant Accounting Policies [Table]
Organization And Significant Accounting Policies [Table]
Sale of Stock
Subsidiary Sale Of Stock [Axis]
Sale of Stock
Sale Of Stock Name Of Transaction [Domain]
Underwritten public offering.
Underwritten Public Offering [Member]
Underwritten Public Offering [Member]
Geographical
Statement Geographical [Axis]
Geographical
Segment Geographical [Domain]
Singapore Economic Development Board [Member]
SINGAPORE
Organization And Significant Accounting Policies [Line Items]
Organization And Significant Accounting Policies [Line Items]
Accumulated deficit
Upfront payment received.
Upfront payment received
Upfront Payment Received
Term loan
Debt Instrument Face Amount
Cash and cash equivalents, including restricted cash
Summary of significant accounting policy.
Schedule of summary of significant accounting policies.
Schedule Of Summary Of Significant Accounting Policies [Table]
Schedule Of Summary Of Significant Accounting Policies [Table]
Concentration Risk Type
Concentration Risk By Type [Axis]
Concentration Risk Type
Concentration Risk Type [Domain]
Credit Risk [Member]
Credit Concentration Risk [Member]
Concentration Risk Benchmark
Concentration Risk By Benchmark [Axis]
Concentration Risk Benchmark
Concentration Risk Benchmark [Domain]
Accounts Receivable [Member]
Accounts Receivable [Member]
Customer Concentration Risk [Member]
Customer Concentration Risk [Member]
Revenue [Member]
Sales Revenue Net [Member]
Customer
Major Customers [Axis]
Customer
Name Of Major Customer [Domain]
Top four customers.
Top Four Customers [Member]
Top Four Customers [Member]
Investment, Name
Schedule Of Equity Method Investment Equity Method Investee Name [Axis]
Investment, Name
Equity Method Investee Name [Domain]
Axcelead, Inc.
Axcelead, Inc [Member]
Axcelead Inc [Member]
Equity Method Investment, Nonconsolidated Investee
Equity Method Investment Nonconsolidated Investee [Axis]
Equity Method Investment, Nonconsolidated Investee
Equity Method Investment Nonconsolidated Investee [Domain]
Vallon Pharmaceuticals, Inc.
Vallon Pharmaceuticals, Inc. [Member]
Vallon Pharmaceuticals Inc [Member]
Statistical Measurement
Range [Axis]
Statistical Measurement
Range [Member]
Maximum [Member]
Maximum [Member]
Minimum [Member]
Minimum [Member]
Accounting Standards Update
Adjustments For New Accounting Pronouncements [Axis]
Accounting Standards Update
Type Of Adoption [Member]
ASU 2014-09 [Member]
Accounting Standards Update201409 [Member]
Vesting
Vesting [Axis]
Vesting
Vesting [Domain]
First Year Anniversary of the Grant [Member]
Share Based Compensation Award Tranche One [Member]
Title of Individual
Title Of Individual [Axis]
Title of Individual
Title Of Individual With Relationship To Entity [Domain]
Employees and officers.
Employees and Officers [Member]
Employees And Officers [Member]
ASC 740 [Member]
Accounting Standards Update201517 [Member]
Summary Of Significant Accounting Policy [Line Items]
Summary Of Significant Accounting Policy [Line Items]
Number of operating segments for research and development
Number Of Operating Segments
Allowance for Doubtful Accounts Receivable
Allowance For Doubtful Accounts Receivable
Concentration risk number of customer.
Number of customers
Concentration Risk Number Of Customer
Concentration risk, percentage
Concentration Risk Percentage1
Equity method ownership percentage
Equity Method Investment Ownership Percentage
Percentage of owned shares
Investment Owned Percent Of Net Assets
Percentage of equity interest in joint venture.
Upfront fee/consideration.
Investment in joint venture
Equity Method Investment Aggregate Cost
Upfront fee/consideration
Upfront Fee And Consideration
Cash consideration paid for equity interest in joint venture
Payments To Acquire Interest In Joint Venture
Percentage of equity interest in joint venture
Percentage Of Equity Interest In Joint Venture
Property and equipment, useful lives
Property Plant And Equipment Useful Life
Impairment losses
Goodwill Impairment Loss
Other comprehensive loss
Other Comprehensive Income Loss Net Of Tax
Income tax effect related to unrealized losses on marketable securities
Other Comprehensive Income Loss Available For Sale Securities Tax
Change in accounting principle, accounting standards update, adopted
Change In Accounting Principle Accounting Standards Update Adopted
Change in accounting principle, accounting standards update, adoption date
Change In Accounting Principle Accounting Standards Update Adoption Date
Share options expiration period
Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period
Vesting period
Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1
Vesting percentage
Sharebased Compensation Arrangement By Sharebased Payment Award Award Vesting Rights Percentage
Vesting description
Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Rights
Non-current restricted cash
Total cash, cash equivalents and restricted cash shown in the statement of cash flows
Change in Accounting Principle, Accounting Standards Update, Immaterial Effect [true false]
Change In Accounting Principle Accounting Standards Update Immaterial Effect
Dividends declared or paid
Dividends
Contract with customer asset additions for revenue recognized.
Contract with customer asset deductions for cash collections.
Contract With Customer Liability Additions For Advanced Billings
Contract Assets, Balance
Contract With Customer Asset Net
Contract Assets, Additions for revenue recognized from billings
Contract With Customer Asset Additions For Revenue Recognized
Contract Assets, Deductions for cash collections
Contract With Customer Asset Deductions For Cash Collections
Contract Assets, Balance
Contract Liabilities, Balance
Contract With Customer Liability
Contract Liabilities, Additions for advanced billings
Contract With Customer Liability Additions For Advanced Billings
Deductions for promised services provided in current period
Contract With Customer Liability Revenue Recognized
Contract Liabilities, Balance
Revenue.
Revenue.
Revenue [Table]
Revenue [Table]
Collaborative Arrangement and Arrangement Other than Collaborative
Type Of Arrangement [Axis]
Collaborative Arrangement and Arrangement Other than Collaborative
Arrangements And Nonarrangement Transactions [Member]
Research collaboration and license agreement.
Research Collaboration And License Agreement [Member]
Research Collaboration And License Agreement [Member]
Foreign countries.
Foreign Countries [Member]
Foreign Countries [Member]
Vinbiocare agreement.
Vinbiocare Agreement [Member]
Vinbiocare Agreement [Member]
ASC 606 [Member]
Janssen.
Janssen [Member]
Janssen [Member]
Research Collaboration and Exclusive License Agreement.
Research Collaboration And Exclusive License Agreement [Member]
Research Collaboration And Exclusive License Agreement [Member]
CureVac AG.
CureVac [Member]
Cure Vac A G [Member]
mRNA technology.
mRNA Technology [Member]
M R N A Technology [Member]
Product and Service
Product Or Service [Axis]
Product and Service
Products And Services [Domain]
Rare disease targets.
Rare Disease Targets [Member]
Rare Disease Targets [Member]
Non-rare disease targets.
Non-Rare Disease Targets [Member]
Non Rare Disease Targets [Member]
Collaboration Partner Cure Vac entered into Co-Development Agreement.
Collaboration Partner Cure Vac Entered Into Co Development Agreement [Member]
Collaboration Partner Cure Vac Entered Into Co Development Agreement [Member]
Other collaboration agreements.
Other Collaboration Agreements [Member]
Other Collaboration Agreements [Member]
Subsequent Event Type
Subsequent Event Type [Axis]
Subsequent Event Type
Subsequent Event Type [Domain]
Subsequent Event [Member]
Subsequent Event [Member]
Related Party
Related Party Transactions By Related Party [Axis]
Related Party
Related Party [Domain]
Pharmaceutical company.
Pharmaceutical Company [Member]
Pharmaceutical Company [Member]
Israeli Ministry of Health ("MOH") [Member]
ILLINOIS
Revenue [Line Items]
Revenue [Line Items]
Collaboration revenue
Disaggregation Of Revenue [Table]
Disaggregation Of Revenue [Table]
Vinbiocare.
Vinbiocare [Member]
Vinbiocare [Member]
SGI.
SGI [Member]
S G I [Member]
Other.
Other [Member]
Other [Member]
Disaggregation Of Revenue [Line Items]
Disaggregation Of Revenue [Line Items]
Total revenue
Number of performance obligations.
Number of performance obligations
Number Of Performance Obligations
Deferred revenue
Revenue recognition potential milestone revenue recognized.
Revenue recognition potential milestone revenue recognized
Revenue Recognition Potential Milestone Revenue Recognized
Remaining performance obligation
Revenue Remaining Performance Obligation
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Start Date [Axis]
Remaining research period
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1
Option exercise revenue range per target.
Option exercise fee revenue received.
Option exercise revenue range per target
Option Exercise Revenue Range Per Target
Option exercise fee received
Option Exercise Fee Revenue Received
Royalty payment term description.
Royalty payment term description
Royalty Payment Term Description
Number of reserve targets.
Option to purchase of additional shares of common stock.
Option to purchase of additional shares of common stock price per share.
Number of targets
Number Of Reserve Targets
Purchase of common stock, shares
Purchase of additional shares of common stock
Option To Purchase Of Additional Shares Of Common Stock
Purchase of additional shares of common stock price per share
Option To Purchase Of Additional Shares Of Common Stock Price Per Share
Collaboration agreement consideration received.
Collaboration agreement transaction price.
Lack of marketability discount restricted period.
Consideration received
Collaboration Agreement Consideration Received
Consideration received for common stock purchase
Sale Of Stock Consideration Received Per Transaction
Transaction price
Collaboration Agreement Transaction Price
Lack of marketability discount restricted period
Lack Of Marketability Discount Restricted Period
Revenue, practical expedient description
Revenue Practical Expedient Remaining Performance Obligation Description
Revenue recognition reserve target exclusivity period.
Revenue recognition, reserve target exclusivity period
Revenue Recognition Reserve Target Exclusivity Period
Development and option agreement date.
Development and option agreement date
Development And Option Agreement Date
Expiration of initial term.
Option to extend initial term on an annual basis.
Expiration of initial term
Expiration Of Intial Term
Option to extend initial term on an annual basis
Option To Extend Initial Term On An Annual Basis
Potential target license term.
Potential target license term
Potential Target License Term
Adjustments to transaction price.
Adjustments to transaction price
Adjustments To Transaction Price
Upfront fee received.
Collaboration agreement contractual term.
Upfront fee received
Upfront Fee Received
Contractual term
Collaboration Agreement Contractual Term
Agreement amount agreed to fund.
Amount agreed to fund
Agreement Amount Agreed To Fund
Non-refundable payment received.
Number of reserved vaccine doses.
Non-refundable payment received
Non Refundable Payment Received
Number of reserved vaccine doses
Number Of Reserved Vaccine Doses
Accrued cystic fibrosis foundation liability.
Accrued singapore economic development board liability.
Clinical accruals current.
Other accrued research and development expenses.
Accrued Liabilities Current [Abstract]
Accrued compensation
Employee Related Liabilities Current
Cystic Fibrosis Foundation liability
Accrued Cystic Fibrosis Foundation Liability
Singapore Economic Development Board liability
Accrued Singapore Economic Development Board Liability
Current portion of operating lease liability
Operating Lease Liability Current
Operating Lease Liability Current Statement Of Financial Position Extensible List
Operating Lease Liability Current Statement Of Financial Position Extensible List
Clinical accruals
Clinical Accruals Current
Other accrued research and development expenses
Other Accrued Research And Development Expenses
Total
Schedule Of Property Plant And Equipment [Table]
Schedule Of Property Plant And Equipment [Table]
Long-Lived Tangible Asset
Property Plant And Equipment By Type [Axis]
Long-Lived Tangible Asset
Property Plant And Equipment Type [Domain]
Research equipment [Member]
Equipment [Member]
Computer and software [Member]
Computer Equipment [Member]
Office equipment and furniture [Member]
Furniture And Fixtures [Member]
Leasehold improvements [Member]
Leasehold Improvements [Member]
Construction in progress [Member]
Construction In Progress [Member]
Property Plant And Equipment [Line Items]
Property Plant And Equipment [Line Items]
Property and equipment, gross
Property Plant And Equipment Gross
Less accumulated depreciation and amortization
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
Property and equipment, net
Potential principal repayments of debt instrument.
Debt Instrument [Table]
Debt Instrument [Table]
Loan and security agreement.
Loan and Security Agreement [Member]
Loan And Security Agreement [Member]
Western Alliance Bank.
Western Alliance Bank [Member]
Western Alliance Bank [Member]
Long-term Debt, Type
Longterm Debt Type [Axis]
Long-term Debt, Type
Longterm Debt Type [Domain]
Long-term Debt [Member]
Long Term Debt [Member]
Debt Instrument [Line Items]
Debt Instrument [Line Items]
Term loan draw down
Borrowings Under Guaranteed Investment Agreements
Potential principal repayment of loan
Potential Principal Repayments Of Debt Instrument
Royalty payment percentage.
Loan accrues interest rate per annum, percentage
Debt Instrument Interest Rate Effective Percentage
Royalty payment percentage of proceeds from net sales
Royalty Payment Percentage
Maximum sales required for loans forgivable .
Maximum LUNAR-COVID 19 sales required for Loans forgivable
Maximum Sales Required For Loans Forgivable
Long-term debt
Long Term Debt
Interest expense related to long-term debt
Interest Expense Long Term Debt
Proceeds from long-term debt agreement
Percentage required to be maintained in consolidated unrestricted cash.
Debt instrument, collateral
Debt Instrument Collateral
Percentage required to be maintain in consolidated, unrestricted cash
Percentage Required To Be Maintained In Consolidated Unrestricted Cash
Debt instrument, collateral amount
Debt Instrument Collateral Amount
Debt instrument interest only payment extended maturity date.
Debt instrument interest only payment extended period.
Net increase in indebtedness
Proceeds From Issuance Of Debt
Loan maturity date
Debt Instrument Maturity Date
Interest of the prime rate plus
Debt Instrument Basis Spread On Variable Rate1
Loan interest-only payment extended maturity date
Debt Instrument Interest Only Payment Extended Maturity Date
Extension to interest only period
Debt Instrument Interest Only Payment Extended Period
Loan first principal payment extended maturity date
Debt Instrument Date Of First Required Payment1
Warrant fee payable.
Loan origination fee paid
Unamortized Loan Commitment And Origination Fees And Unamortized Discounts Or Premiums
Warrant fee payable
Warrant Fee Payable
Prepayment fee percentage.
Prepayment fee percentage
Prepayment Fee Percentage
2022
Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
2023
Long Term Debt Maturities Repayments Of Principal In Year Two
Total
Schedule Of Stock By Class [Table]
Schedule Of Stock By Class [Table]
Alexion Pharmaceuticals, Inc.
Alexion [Member]
Alexion Pharmaceuticals Inc [Member]
Antidilutive Securities
Antidilutive Securities Excluded From Computation Of Earnings Per Share By Antidilutive Securities [Axis]
Antidilutive Securities, Name
Antidilutive Securities Name [Domain]
Unvested restricted ordinary shares.
Unvested Restricted Ordinary Shares [Member]
Unvested Restricted Ordinary Shares [Member]
Class Of Stock [Line Items]
Class Of Stock [Line Items]
Issuance of common stock
Common stock issued, value
Stock Issued During Period Value Issued For Services
Antidilutive securities excluded from computation of earnings per share
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]
Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]
Plan Name
Plan Name [Axis]
Plan Name
Plan Name [Domain]
2021 Inducement equity incentive plan.
2021 Inducement Equity Incentive Plan [Member]
Twenty Twenty One Inducement Equity Incentive Plan [Member]
Award Type
Award Type [Axis]
Award Type
Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain]
Stock Option [Member]
Employee Stock Option [Member]
Two thousand nineteen omnibus incentive plan.
2019 Omnibus Equity Incentive Plan [Member]
Two Thousand Nineteen Omnibus Incentive Plan [Member]
Two Thousand Twenty Employee Stock Purchase Plan.
2020 Employee Stock Purchase Plan [Member]
Two Thousand Twenty Employee Stock Purchase Plan [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of shares available
Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
Common stock reserved for future issuance
Common Stock Capital Shares Reserved For Future Issuance
Share-based compensation number of shares authorized
Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized
Common stock purchased
Share Based Compensation Arrangement By Share Based Payment Award Shares Purchased For Award
Share-based compensation arrangement by share-based payment award, maximum discounted purchase price.
Share based compensation arrangement by share based payment award maximum discounted amount.
Maximum discounted purchase price
Share Based Compensation Arrangement By Share Based Payment Award Maximum Discounted Purchase Price
Share-based compensation expenses
Allocated Share Based Compensation Expense
Maximum discounted amount per year
Share Based Compensation Arrangement By Share Based Payment Award Maximum Discounted Amount
Expected life (in years)
Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
Expected volatility
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
Expected dividend yield
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
Risk-free interest rate
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
Grant date weighted average fair value
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
Number of Shares, Outstanding
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
Number of Shares, Granted
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
Number of Shares, Exercised
Number of Shares, Forfeited/cancelled
Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
Number of Shares, Outstanding
Number of Shares, Exercisable December 31, 2021
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
Number of Shares, Exercisable and expected to vest December 31, 2021
Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number
Weighted-Average Exercise Price, Outstanding
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
Weighted-Average Exercise Price, Granted
Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
Weighted-Average Exercise Price, Exercised
Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
Weighted-Average Exercise Price, Forfeited/cancelled
Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
Weighted-Average Exercise Price, Outstanding
Weighted-Average Exercise Price, Exercisable - December 31, 2021
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
Weighted-Average Exercise Price, Exercisable and expected to vest -December 31, 2021
Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price
Weighted-Average Remaining Contractual Term (Years), Outstanding - December 31, 2021
Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
Weighted-Average Remaining Contractual Term (Years), Exercisable - December 31, 2021
Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
Weighted-Average Remaining Contractual Term (Years), Exercisable and expected to vest - December 31, 2021
Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1
Aggregate Intrinsic Value, Exercised
Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
Aggregate Intrinsic Value, Outstanding - December 31, 2021
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
Aggregate Intrinsic Value, Exercisable - December 31, 2021
Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
Aggregate Intrinsic Value, Exercisable and expected to vest - December 31, 2021
Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value
Compensation cost not yet recognized
Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
Weighted-average remaining service period
Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
Fair value of options vested
Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
The total intrinsic value of options exercised
Income Statement Location
Income Statement Location [Axis]
Income Statement Location
Income Statement Location [Domain]
Research and Development [Member]
Research And Development Expense [Member]
General and Administrative [Member]
General And Administrative Expense [Member]
Share-based compensation expenses
United States
Income Loss From Continuing Operations Before Income Taxes Domestic
Foreign
Income Loss From Continuing Operations Before Income Taxes Foreign
Total loss before income taxes
Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
Maximum percentage of likelihood of uncertain tax position recognized to be sustained.
Income taxes.
Income taxes.
Income Taxes [Table]
Income Taxes [Table]
United States [Member]
UNITED STATES
California [Member]
CALIFORNIA
Income Tax Authority
Income Tax Authority [Axis]
Income Tax Authority
Income Tax Authority [Domain]
Federal [Member]
Domestic Country [Member]
State [Member]
State And Local Jurisdiction [Member]
Tax Credit Carryforward
Tax Credit Carryforward [Axis]
Tax Credit Carryforward, Name
Tax Credit Carryforward Name [Domain]
Research Tax Credit Carryforward [Member]
Research [Member]
Orphan drug credit.
Orphan Drug Credit [Member]
Orphan Drug Credit [Member]
Income Taxes [Line Items]
Income Taxes [Line Items]
Maximum percentage of likelihood of uncertain tax position recognized to be sustained
Maximum Percentage Of Likelihood Of Uncertain Tax Position Recognized To Be Sustained
Unrecognized tax benefits (decreases) increases resulting from prior period tax positions.
Reconciliation Of Unrecognized Tax Benefits Excluding Amounts Pertaining To Examined Tax Returns Roll Forward
Beginning balance of unrecognized tax benefits
Unrecognized Tax Benefits
Settlement of prior period tax positions
Unrecognized Tax Benefits Decreases Resulting From Settlements With Taxing Authorities
(Decrease) increase for prior period tax positions
Unrecognized Tax Benefits Decreases Increases Resulting From Prior Period Tax Positions
Increase for current period tax positions
Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
Ending balance of unrecognized tax benefits
Unrecognized Tax Benefits
Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense
Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
Unrecognized tax benefits impacting effective tax rate
Unrecognized Tax Benefits That Would Impact Effective Tax Rate
Deferred tax assets property, plant and equipment and intangible assets.
Deferred tax assets, lease liability.
Deferred tax assets property, plant and equipment and intangible assets.
Deferred tax liabilities, right-of-use asset.
Deferred tax assets:
Deferred Tax Assets Gross [Abstract]
Net operating loss
Deferred Tax Assets Operating Loss Carryforwards
Tax credits
Deferred Tax Assets Tax Credit Carryforwards
Accrued liabilities
Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
Deferred revenue
Deferred Tax Assets Deferred Income
Inventory
Deferred Tax Assets Inventory
Basis difference in equity investments
Deferred Tax Assets Equity Method Investments
Depreciation and amortization
Deferred Tax Assets Property Plant And Equipment And Intangible Assets
Lease liability
Deferred Tax Assets Lease Liability
Share-based compensation
Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
Total gross deferred tax assets
Deferred Tax Assets Gross
Deferred tax liabilities:
Deferred Tax Liabilities [Abstract]
Depreciation and amortization
Deferred Tax Liabilities Property Plant And Equipment And Intangible Assets
Right-of-use asset
Deferred Tax Liabilities Right Of Use Asset
Valuation allowance
Deferred Tax Assets Valuation Allowance
Net deferred tax asset
Deferred Tax Assets Liabilities Net
Federal net operating losses offset percent.
Operating loss carryforwards expiration year.
Operating Loss Carryforwards
Operating Loss Carryforwards
Operating Loss Carryforwards Expiration Year
Operating Loss Carryforwards Expiration Year
Federal net operating losses offset percent
Federal Net Operating Losses Offset Percent
Tax credit carryforward expiration year.
Credit Carryforward Amount
Tax Credit Carryforward Amount
Credit Carryforward Expiration Year
Tax Credit Carryforward Expiration Year
Net operating loss and research and development credit carryforwards limitations on cumulative change in ownership minimum percentage.
Net operating loss and research and development credit carryforwards limitations on cumulative change in ownership period.
Net Operating Loss and Research and Development Credit Carryforwards Limitations On Cumulative Change In Ownership Minimum Percentage
Net Operating Loss And Research And Development Credit Carryforwards Limitations On Cumulative Change In Ownership Minimum Percentage
Net Operating Loss and Research and Development Credit Carryforwards Limitations on Cumulative Change In Ownership Period
Net Operating Loss And Research And Development Credit Carryforwards Limitations On Cumulative Change In Ownership Period
Effective income tax rate reconciliation nondeductible expense officers compensation.
Effective income tax rate reconciliation uncertain tax position.
Federal statutory income tax rate
Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
State income taxes, net of federal benefit
Effective Income Tax Rate Reconciliation State And Local Income Taxes
Foreign rate differential
Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential
Share-based compensation
Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
Officers compensation
Effective Income Tax Rate Reconciliation Nondeductible Expense Officers Compensation
Research and development credits
Effective Income Tax Rate Reconciliation Nondeductible Expense Research And Development
Uncertain tax position
Effective Income Tax Rate Reconciliation Uncertain Tax Position
Change in tax rate
Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
Foreign net operating losses
Effective Income Tax Rate Reconciliation Repatriation Of Foreign Earnings
Change in valuation allowance
Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
Other
Effective Income Tax Rate Reconciliation Tax Credits Other
Permanent differences
Effective Income Tax Rate Reconciliation Other Adjustments
Provision for income taxes
Effective Income Tax Rate Continuing Operations
Contra research and development expense.
Contra expense remaining amount included in accrued expenses.
Commitment and contingencies.
Commitment and contingencies.
Commitment And Contingencies [Table]
Commitment And Contingencies [Table]
COVID-19 vaccine development.
COVID-19 Vaccine Development [Member]
C O V I D Nineteen Vaccine Development [Member]
Grant one.
Grant 1 [Member]
Grant One [Member]
Grant two.
Grant 2 [Member]
Grant Two [Member]
LUNAR-CF.
LUNAR-CF [Member]
L U N A R C F [Member]
Underlying agreement.
Underlying Agreement [Member]
Underlying Agreement [Member]
Cystic Fibrosis Foundation Therapeutics, Inc.
Cystic Fibrosis Foundation [Member]
Cystic Fibrosis Foundation Therapeutics Inc [Member]
Scenario
Statement Scenario [Axis]
Scenario
Scenario Unspecified [Domain]
Disbursement period one.
Disbursement Due January 2020 [Member]
Disbursement Period One [Member]
Disbursement period two.
Disbursement Due April 2020 [Member]
Disbursement Period Two [Member]
Disbursement period three.
Disbursement Due July 2020 [Member]
Disbursement Period Three [Member]
Disbursement period four.
Disbursement Due October 2020 [Member]
Disbursement Period Four [Member]
October 2017 lease amendment.
October 2017 Lease Amendment [Member]
October Two Thousand And Seventeen Lease Amendment [Member]
Lease Contractual Term
Lease Contractual Term [Axis]
Lease Contractual Term
Lease Contractual Term [Domain]
September two thousand and twenty one lease agreement.
September 2021 Lease Agreement [Member]
September Two Thousand And Twenty One Lease Agreement [Member]
Commitment And Contingencies [Line Items]
Commitment And Contingencies [Line Items]
Grants Receivable
Grants Receivable
Contra research and development expense recognized
Contra Research And Development Expense
Contra expense remaining amount included in accrued expenses
Contra Expense Remaining Amount Included In Accrued Expenses
Grant receivable number of installments.
Payment received first installment.
Recognized contra expense.
Grant, number of installments
Grant Receivable Number Of Installments
Received first installment
Payment Received First Installment
Contra expense
Recognized Contra Expense
Accrued expenses
Accrued Liabilities Fair Value Disclosure
Payments for matching funds for remaining budgeted costs.
Disbursed amount upon execution of amendment.
Disbursement amount payable upon achievement of project goal.
Final payment of disbursement amount.
Disbursement payment upon achievement of required manufacturing practices and IND application.
Contra expense included in research and development expense.
Payments for advance
Payments For Advance To Affiliate
Payments for matching funds for remaining budgeted costs
Payments For Matching Funds For Remaining Budgeted Costs
Disbursed amount upon execution of amendment
Disbursed Amount Upon Execution Of Amendment
Disbursement amount payable upon achievement of project goal
Disbursement Amount Payable Upon Achievement Of Project Goal
Final payment of disbursement amount
Final Payment Of Disbursement Amount
Disbursement payment upon achievement of required manufacturing practices and IND application
Disbursement Payment Upon Achievement Of Required Manufacturing Practices And I N D Application
Contra expense included in research and development expense
Contra Expense Included In Research And Development Expense
Operating lease extended additional term
Lessee Operating Lease Renewal Term
Lessee, operating lease, term of contract
Lessee Operating Lease Term Of Contract
Tenant improvement allowance
Payments For Proceeds From Tenant Allowance
Lessee, operating leases, option to extend
Lessee Operating Lease Option To Extend
Security deposit
Security Deposit
Monthly base rent.
Monthly base rent
Monthly Base Rent
Leases [Abstract]
2022
Lessee Operating Lease Liability Payments Due Next Twelve Months
2023
Lessee Operating Lease Liability Payments Due Year Two
2024
Lessee Operating Lease Liability Payments Due Year Three
Thereafter
Lessee Operating Lease Liability Payments Due After Year Five
Total remaining lease payments
Lessee Operating Lease Liability Payments Due
Less: imputed interest
Lessee Operating Lease Liability Undiscounted Excess Amount
Total operating lease liabilities
Operating Lease Liability
Weighted-average remaining lease term
Operating Lease Weighted Average Remaining Lease Term1
Weighted-average discount rate
Operating Lease Weighted Average Discount Rate Percent
Operating lease costs
Operating Lease Cost
Common stock shares restricted from selling period subsequent to issuance date.
Schedule Of Related Party Transactions By Related Party [Table]
Schedule Of Related Party Transactions By Related Party [Table]
Collaboration partner Ultragenyx.
Collaboration Partner - Ultragenyx [Member]
Collaboration Partner Ultragenyx [Member]
Related Party Transaction [Line Items]
Related Party Transaction [Line Items]
Common stock shares restricted from selling period subsequent to issuance date
Common Stock Shares Restricted From Selling Period Subsequent To Issuance Date
Ownership interest of common stock
Sale Of Stock Percentage Of Ownership After Transaction
ADAIR Technology.
ADAIR Technology [Member]
A D A I R Technology [Member]
Number of shares owned
Investment Owned Balance Shares
Share price
Share Price
Research and development expenses, net
General and administrative expenses
Loss from operations